289 related articles for article (PubMed ID: 20708999)
1. IRX-2 increases the T cell-specific immune response to protein/peptide vaccines.
Naylor PH; Hernandez KE; Nixon AE; Brandwein HJ; Haas GP; Wang CY; Hadden JW
Vaccine; 2010 Oct; 28(43):7054-62. PubMed ID: 20708999
[TBL] [Abstract][Full Text] [Related]
2. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
3. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
4. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
5. Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant.
Chaitra MG; Nayak R; Shaila MS
Vaccine; 2007 Oct; 25(41):7168-76. PubMed ID: 17709160
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
7. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
[TBL] [Abstract][Full Text] [Related]
8. A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites.
Meraldi V; Romero JF; Kensil C; Corradin G
Vaccine; 2005 Apr; 23(21):2801-12. PubMed ID: 15780728
[TBL] [Abstract][Full Text] [Related]
9. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
11. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
12. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response.
Nguyen CL; Bui JT; Demcheva M; Vournakis JN; Cole DJ; Gillanders WE
J Immunother; 2001; 24(5):420-9. PubMed ID: 11696697
[TBL] [Abstract][Full Text] [Related]
13. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
14. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model.
Otero M; Calarota SA; Felber B; Laddy D; Pavlakis G; Boyer JD; Weiner DB
Vaccine; 2004 Apr; 22(13-14):1782-90. PubMed ID: 15068862
[TBL] [Abstract][Full Text] [Related]
15. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
16. Poly(gamma-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine.
Wang X; Uto T; Akagi T; Akashi M; Baba M
J Med Virol; 2008 Jan; 80(1):11-9. PubMed ID: 18041033
[TBL] [Abstract][Full Text] [Related]
17. Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response.
Parajuli P; Pisarev V; Sublet J; Steffel A; Varney M; Singh R; LaFace D; Talmadge JE
Cancer Res; 2001 Nov; 61(22):8227-34. PubMed ID: 11719454
[TBL] [Abstract][Full Text] [Related]
18. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.
Speiser DE; Liénard D; Rufer N; Rubio-Godoy V; Rimoldi D; Lejeune F; Krieg AM; Cerottini JC; Romero P
J Clin Invest; 2005 Mar; 115(3):739-46. PubMed ID: 15696196
[TBL] [Abstract][Full Text] [Related]
19. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
20. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
Knutson KL; Disis ML
Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
